Point-of-care testing for gastrointestinal pathogens (GastroPOC) v1.0

  • Research type

    Research Study

  • Full title

    Randomised controlled trial comparing molecular Point-of-Care testing for gastrointestinal pathogens with standard clinical care, in adults presenting to secondary care with suspected infectious gastroenteritis: a pilot study (GastroPOC Trial).

  • IRAS ID

    208839

  • Contact name

    Tristan Clark

  • Contact email

    t.w.clark@soton.ac.uk

  • Sponsor organisation

    R&D, University Hospital Southampton NHS Foundation Trust

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    This study will examine the clinical impact of a rapid, molecular, point-of-care test (POCT) for gastrointestinal pathogens detection (FilmArray Gastrointestinal Panel, BioFire, Salt Lake City, Utah, USA, owned by bioMérieux; CE marked) in patients presenting with acute diarrhoea and/or vomiting, compared to routine clinical care in a pilot randomised controlled trial. Screened, eligible and consented adults with acute diarrhoea and/or vomiting in the Acute Medical Unit, Acute Surgical Unit, Emergency Department and inpatient wards of Southampton General Hospital will be randomised to either have a stool sample (or rectal swab) taken and tested for gastrointestinal pathogens by the POCT, or to routine clinical care alone. The participant will be informed of the result if tested. If an infection is detected, the clinical team responsible for patient care will be informed of the result directly.

    The clinical impact of this rapid gastrointestinal infection detection test will assessed by measures including, but not limited to, use of isolation facilities, duration of hospital stay, use of antibiotics, rate of pathogen detection and time to diagnosis.

    The study recruitment period will be across at least one year to include the typical peak periods for some pathogens with seasonal incidence such as norovirus and Campylobacter. It is designed as a pilot study to provide data to inform the design of a larger randomised controlled trial and health economic analysis planned for the future.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    16/WM/0515

  • Date of REC Opinion

    9 Jan 2017

  • REC opinion

    Further Information Favourable Opinion